{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:27:31Z","timestamp":1780489651684,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinicians often hesitate prescribing corticosteroids to treat corticosteroid-responsive conditions in sickle cell disease (SCD) patients because their use can be associated with complications (increased hospital readmission, rebound pain, strokes, avascular necrosis, acute chest syndrome). Consequently, SCD patients may receive suboptimal treatment for corticosteroid-responsive conditions. We conducted a preclinical trial of dissociative (vamorolone) and conventional (prednisolone) corticosteroid compounds to evaluate their effects on nociception phenotype, inflammation, and organ dysfunction in SCD mice. Prednisolone and vamorolone had no significant effects on nociception phenotype or anemia in homozygous mice. Conversely, prednisolone and vamorolone significantly decreased white blood cell counts and hepatic inflammation. Interestingly, the effects of vamorolone were milder than those of prednisolone, as vamorolone yielded less attenuation of hepatic inflammation compared to prednisolone. Compared to controls and heterozygotes, homozygotes had significant liver necrosis, which was significantly exacerbated by prednisolone and vamorolone despite decreased hepatic inflammation. These hepatic histopathologic changes were associated with increases in transaminases and alkaline phosphatase. Together, these results suggest that, even in the setting of decreasing hepatic inflammation, prednisolone and vamorolone were associated with significant hepatic toxicity in SCD mice. These findings raise the possibility that hepatic function deterioration could occur with the use of corticosteroids (conventional and dissociative) in SCD.<\/jats:p>","DOI":"10.1038\/s41598-018-24274-6","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T09:15:50Z","timestamp":1523438150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice"],"prefix":"10.1038","volume":"8","author":[{"given":"Luis E. F.","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse M.","family":"Damsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenaide M. N.","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"24274_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel, F. B., Steinberg, M. H. & Rees, D. C. Sickle Cell Disease. New England Journal of Medicine 376, 1561\u20131573, https:\/\/doi.org\/10.1056\/NEJMra1510865 (2017).","journal-title":"New England Journal of Medicine"},{"key":"24274_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn, B. P. et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312, 1033\u20131048, https:\/\/doi.org\/10.1001\/jama.2014.10517 (2014).","journal-title":"JAMA"},{"key":"24274_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24856","author":"A Solovey","year":"2017","unstructured":"Solovey, A. et al. A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.24856 (2017).","journal-title":"Am J Hematol"},{"key":"24274_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1189\/jlb.0708445","volume":"85","author":"C Lanaro","year":"2009","unstructured":"Lanaro, C. et al. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 85, 235\u2013242, https:\/\/doi.org\/10.1189\/jlb.0708445 (2009).","journal-title":"J Leukoc Biol"},{"key":"24274_CR5","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","volume":"120","author":"SK Ballas","year":"2012","unstructured":"Ballas, S. K., Gupta, K. & Adams-Graves, P. Sickle cell pain: a critical reappraisal. Blood 120, 3647\u20133656, https:\/\/doi.org\/10.1182\/blood-2012-04-383430 (2012).","journal-title":"Blood"},{"key":"24274_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cyto.2014.11.030","volume":"72","author":"S Sarray","year":"2015","unstructured":"Sarray, S. et al. Serum IL-6, IL-10, and TNFalpha levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition. Cytokine 72, 43\u201347, https:\/\/doi.org\/10.1016\/j.cyto.2014.11.030 (2015).","journal-title":"Cytokine"},{"key":"24274_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.hoc.2013.11.005","volume":"28","author":"RP Hebbel","year":"2014","unstructured":"Hebbel, R. P. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am 28, 181\u2013198, https:\/\/doi.org\/10.1016\/j.hoc.2013.11.005 (2014).","journal-title":"Hematol Oncol Clin North Am"},{"key":"24274_CR8","doi-asserted-by":"publisher","first-page":"e94387","DOI":"10.1371\/journal.pone.0094387","volume":"9","author":"V Allareddy","year":"2014","unstructured":"Allareddy, V. et al. Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality. PLoS One 9, e94387, https:\/\/doi.org\/10.1371\/journal.pone.0094387 (2014).","journal-title":"PLoS One"},{"key":"24274_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-0609.2011.01647.x","volume":"87","author":"RN Paul","year":"2011","unstructured":"Paul, R. N., Castro, O. L., Aggarwal, A. & Oneal, P. A. Acute chest syndrome: sickle cell disease. Eur J Haematol 87, 191\u2013207, https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01647.x (2011).","journal-title":"Eur J Haematol"},{"key":"24274_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1517\/14656566.2013.783570","volume":"14","author":"PC Desai","year":"2013","unstructured":"Desai, P. C. & Ataga, K. I. The acute chest syndrome of sickle cell disease. Expert Opin Pharmacother 14, 991\u2013999, https:\/\/doi.org\/10.1517\/14656566.2013.783570 (2013).","journal-title":"Expert Opin Pharmacother"},{"key":"24274_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cyto.2017.05.017","volume":"97","author":"VT Garrido","year":"2017","unstructured":"Garrido, V. T. et al. Association of plasma CD40L with acute chest syndrome in sickle cell anemia. Cytokine 97, 104\u2013107, https:\/\/doi.org\/10.1016\/j.cyto.2017.05.017 (2017).","journal-title":"Cytokine"},{"key":"24274_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2141.2011.08827.x","volume":"155","author":"CT Quinn","year":"2011","unstructured":"Quinn, C. T. et al. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol 155, 263\u2013267, https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08827.x (2011).","journal-title":"Br J Haematol"},{"key":"24274_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ajh.24742","volume":"92","author":"J Glassberg","year":"2017","unstructured":"Glassberg, J. et al. Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized trial. Am J Hematol 92, 622\u2013631, https:\/\/doi.org\/10.1002\/ajh.24742 (2017).","journal-title":"Am J Hematol"},{"key":"24274_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJM199403173301101","volume":"330","author":"TC Griffin","year":"1994","unstructured":"Griffin, T. C., McIntire, D. & Buchanan, G. R. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 330, 733\u2013737, https:\/\/doi.org\/10.1056\/NEJM199403173301101 (1994).","journal-title":"N Engl J Med"},{"key":"24274_CR15","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V92.9.3082","volume":"92","author":"JC Bernini","year":"1998","unstructured":"Bernini, J. C. et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 92, 3082\u20133089 (1998).","journal-title":"Blood"},{"key":"24274_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/pbc.23221","volume":"58","author":"A Sobota","year":"2012","unstructured":"Sobota, A., Graham, D. A., Neufeld, E. J. & Heeney, M. M. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children\u2019s hospitals: risk factors and hospital variation. Pediatr Blood Cancer 58, 61\u201365, https:\/\/doi.org\/10.1002\/pbc.23221 (2012).","journal-title":"Pediatr Blood Cancer"},{"key":"24274_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajh.21708","volume":"85","author":"A Sobota","year":"2010","unstructured":"Sobota, A., Graham, D. A., Heeney, M. M. & Neufeld, E. J. Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol 85, 24\u201328, https:\/\/doi.org\/10.1002\/ajh.21565 (2010).","journal-title":"Am J Hematol"},{"key":"24274_CR18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0027-9684(15)31410-3","volume":"100","author":"DS Darbari","year":"2008","unstructured":"Darbari, D. S. et al. Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc 100, 948\u2013951 (2008).","journal-title":"J Natl Med Assoc"},{"key":"24274_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/pbc.21336","volume":"50","author":"JJ Strouse","year":"2008","unstructured":"Strouse, J. J., Takemoto, C. M., Keefer, J. R., Kato, G. J. & Casella, J. F. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 50, 1006\u20131012, https:\/\/doi.org\/10.1002\/pbc.21336 (2008).","journal-title":"Pediatr Blood Cancer"},{"key":"24274_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.prrv.2013.10.004","volume":"15","author":"F Ogunlesi","year":"2014","unstructured":"Ogunlesi, F., Heeney, M. M. & Koumbourlis, A. C. Systemic corticosteroids in acute chest syndrome: friend or foe? Paediatr Respir Rev 15, 24\u201327, https:\/\/doi.org\/10.1016\/j.prrv.2013.10.004 (2014).","journal-title":"Paediatr Respir Rev"},{"key":"24274_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.112.194340","volume":"343","author":"AR Baudy","year":"2012","unstructured":"Baudy, A. R. et al. Delta-9,11 modification of glucocorticoids dissociates nuclear factor-kappaB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther 343, 225\u2013232, https:\/\/doi.org\/10.1124\/jpet.112.194340 (2012).","journal-title":"J Pharmacol Exp Ther"},{"key":"24274_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pupt.2016.04.004","volume":"38","author":"LM Garvin","year":"2016","unstructured":"Garvin, L. M., Chen, Y., Damsker, J. M. & Rose, M. C. A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone. Pulm Pharmacol Ther 38, 17\u201326, https:\/\/doi.org\/10.1016\/j.pupt.2016.04.004 (2016).","journal-title":"Pulm Pharmacol Ther"},{"key":"24274_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00011-016-0956-8","volume":"65","author":"JM Damsker","year":"2016","unstructured":"Damsker, J. M. et al. VBP15, a novel dissociative steroid compound, reduces NFkappaB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis. Inflamm Res 65, 737\u2013743, https:\/\/doi.org\/10.1007\/s00011-016-0956-8 (2016).","journal-title":"Inflamm Res"},{"key":"24274_CR24","doi-asserted-by":"publisher","first-page":"e63871","DOI":"10.1371\/journal.pone.0063871","volume":"8","author":"JM Damsker","year":"2013","unstructured":"Damsker, J. M. et al. VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice. PLoS One 8, e63871, https:\/\/doi.org\/10.1371\/journal.pone.0063871 (2013).","journal-title":"PLoS One"},{"key":"24274_CR25","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","volume":"21","author":"EK Reeves","year":"2013","unstructured":"Reeves, E. K., Hoffman, E. P., Nagaraju, K., Damsker, J. M. & McCall, J. M. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem 21, 2241\u20132249, https:\/\/doi.org\/10.1016\/j.bmc.2013.02.009 (2013).","journal-title":"Bioorg Med Chem"},{"key":"24274_CR26","doi-asserted-by":"publisher","first-page":"9366","DOI":"10.18632\/oncotarget.14070","volume":"8","author":"E Wells","year":"2017","unstructured":"Wells, E. et al. Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget 8, 9366\u20139374, https:\/\/doi.org\/10.18632\/oncotarget.14070 (2017).","journal-title":"Oncotarget"},{"key":"24274_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.nbd.2015.10.004","volume":"85","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Cognitive and behavior deficits in sickle cell mice are associated with profound neuropathologic changes in hippocampus and cerebellum. Neurobiol Dis 85, 60\u201372, https:\/\/doi.org\/10.1016\/j.nbd.2015.10.004 (2016).","journal-title":"Neurobiol Dis"},{"key":"24274_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1535370214544275","volume":"240","author":"N Kenyon","year":"2015","unstructured":"Kenyon, N. et al. Sickle cell disease in mice is associated with sensitization of sensory nerve fibers. Exp Biol Med (Maywood) 240, 87\u201398, https:\/\/doi.org\/10.1177\/1535370214544275 (2015).","journal-title":"Exp Biol Med (Maywood)"},{"key":"24274_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejphar.2015.02.027","volume":"754","author":"G Calhoun","year":"2015","unstructured":"Calhoun, G. et al. Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice. Eur J Pharmacol 754, 125\u2013133, https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.027 (2015).","journal-title":"Eur J Pharmacol"},{"key":"24274_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bcmd.2015.08.001","volume":"55","author":"A Khaibullina","year":"2015","unstructured":"Khaibullina, A. et al. Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. Blood Cells Mol Dis 55, 363\u2013372, https:\/\/doi.org\/10.1016\/j.bcmd.2015.08.001 (2015).","journal-title":"Blood Cells Mol Dis"},{"key":"24274_CR31","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","volume":"108","author":"LC Wu","year":"2006","unstructured":"Wu, L. C. et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108, 1183\u20131188, https:\/\/doi.org\/10.1182\/blood-2006-02-004812 (2006).","journal-title":"Blood"},{"key":"24274_CR32","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1126\/science.1152092","volume":"318","author":"J Hanna","year":"2007","unstructured":"Hanna, J. et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920\u20131923, https:\/\/doi.org\/10.1126\/science.1152092 (2007).","journal-title":"Science"},{"key":"24274_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3324\/haematol.10800","volume":"92","author":"S Couillard","year":"2007","unstructured":"Couillard, S. et al. Steroid treatment in children with sickle-cell disease. Haematologica 92, 425\u2013426 (2007).","journal-title":"Haematologica"},{"key":"24274_CR34","doi-asserted-by":"publisher","first-page":"H2715","DOI":"10.1152\/ajpheart.00986.2004","volume":"288","author":"JD Belcher","year":"2005","unstructured":"Belcher, J. D. et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol 288, H2715\u20132725, https:\/\/doi.org\/10.1152\/ajpheart.00986.2004 (2005).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"24274_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1053\/j.gastro.2012.08.029","volume":"143","author":"Y Lu","year":"2012","unstructured":"Lu, Y. et al. Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid X receptor. Gastroenterology 143, 1630\u20131640. e1638, https:\/\/doi.org\/10.1053\/j.gastro.2012.08.029 (2012).","journal-title":"Gastroenterology"},{"key":"24274_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1139\/bcb-2016-0070","volume":"95","author":"O Lisakovska","year":"2017","unstructured":"Lisakovska, O., Shymanskyy, I., Mazanova, A., Khomenko, A. & Veliky, M. Vitamin D3 protects against prednisolone-induced liver injury associated with the impairment of the hepatic NF-kappaB\/iNOS\/NO pathway. Biochem Cell Biol 95, 213\u2013222, https:\/\/doi.org\/10.1139\/bcb-2016-0070 (2017).","journal-title":"Biochem Cell Biol"},{"key":"24274_CR37","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1172\/JCI89741","volume":"127","author":"GJ Kato","year":"2017","unstructured":"Kato, G. J., Steinberg, M. H. & Gladwin, M. T. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 127, 750\u2013760, https:\/\/doi.org\/10.1172\/jci89741 (2017).","journal-title":"J Clin Invest"},{"key":"24274_CR38","doi-asserted-by":"publisher","unstructured":"Ebert, E. C., Nagar, M. & Hagspiel, K. D. Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol 8, 483\u2013489; quiz e470, https:\/\/doi.org\/10.1016\/j.cgh.2010.02.016 (2010).","DOI":"10.1016\/j.cgh.2010.02.016"},{"key":"24274_CR39","doi-asserted-by":"publisher","unstructured":"National Research Council. Guide for the Care and Use of Laboratory Animals. https:\/\/doi.org\/10.17226\/12910 (The National Academies Press, 2011).","DOI":"10.17226\/12910"},{"key":"24274_CR40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-6997(24)01514-X","volume":"53","author":"D Le Bars","year":"2001","unstructured":"Le Bars, D., Gozariu, M. & Cadden, S. W. Animal models of nociception. Pharmacol Rev 53, 597\u2013652 (2001).","journal-title":"Pharmacol Rev"},{"key":"24274_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-1-13","volume":"1","author":"K Koga","year":"2005","unstructured":"Koga, K. et al. Selective activation of primary afferent fibers evaluated by sine-wave electrical stimulation. Mol Pain 1, 13 (2005).","journal-title":"Mol Pain"},{"key":"24274_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00000542-200608000-00020","volume":"105","author":"JC Finkel","year":"2006","unstructured":"Finkel, J. C. et al. Effects of aging on current vocalization threshold in mice measured by a novel nociception assay. Anesthesiology 105, 360\u2013369 (2006).","journal-title":"Anesthesiology"},{"key":"24274_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.niox.2011.12.004","volume":"26","author":"J Finkel","year":"2012","unstructured":"Finkel, J. et al. The three isoforms of nitric oxide synthase distinctively affect mouse nocifensive behavior. Nitric Oxide 26, 81\u201388, https:\/\/doi.org\/10.1016\/j.niox.2011.12.004 (2012).","journal-title":"Nitric Oxide"},{"key":"24274_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jneumeth.2011.08.011","volume":"201","author":"N Spornick","year":"2011","unstructured":"Spornick, N. et al. Mouse current vocalization threshold measured with a neurospecific nociception assay: the effect of sex, morphine, and isoflurane. J Neurosci Methods 201, 390\u2013398, https:\/\/doi.org\/10.1016\/j.jneumeth.2011.08.011 (2011).","journal-title":"J Neurosci Methods"},{"key":"24274_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/0-89603-472-0:101","volume":"108","author":"K Yagi","year":"1998","unstructured":"Yagi, K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 108, 101\u2013106, https:\/\/doi.org\/10.1385\/0-89603-472-0:101 (1998).","journal-title":"Methods Mol Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24274-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:42:08Z","timestamp":1751557328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["24274"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-24274-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"6 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jesse Damsker is an employee of ReveraGen BioPharma Inc. All other authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6081"}}